Lilly licenses anti-inflammatory from Incyte in deal worth up to $755 million
This article was originally published in Scrip
Executive Summary
Lilly has licensed from Incyte worldwide rights to an oral JAK1/JAK2 inhibitor in a Phase II dose-ranging study for rheumatoid arthritis. Under the development and commercialisation pact, Lilly also has rights to certain follow-on compounds.